TargetMol

Persicogenin

Product Code:
 
TAR-TN2058
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TN2058-1mg1mg£166.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN2058-5mg5mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN2058-1mL1 mL * 10 mM (in DMSO)£326.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN2058-10mg10mg£415.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN2058-25mg25mg£630.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN2058-50mg50mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN2058-100mg100mg£1,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Persicogenin has anticancer, antimutagenic, and antileishmanial activities, it can inhibit the proliferation of mouse tsFT210 cancer cells, it mainly inhibits cell cycle at the G2/M phase in a dose-dependent manner.
CAS:
28590-40-1
Formula:
C17H16O6
Molecular Weight:
316.309
Pathway:
Microbiology/Virology
Purity:
0.978
SMILES:
COc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccc(OC)c(O)c1
Target:
Anti-infection

References

Antimycobacterial activity and cytotoxicity of flavonoids from the flowers of Chromolaena odorata.Arch Pharm Res. 2004 May;27(5):507-11.